Patients with HER2-positive MBC or recurrent breast cancer (RBC) with BM treated with this combination therapy had a significantly longer survival than those treated with trastuzumab alone, lapatinib alone, or no HER2-targeted therapy (p < 0.001) [77]. This evidence concerns the gene ERBB2 and breast cancer.